Trial Profile
A Phase 1, Dose Escalating Study of the Safety, Tolerability, and Pharmacokinetics of IL-1-Ra Topically Administered to Eyes of Healthy Adult Subjects
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Interleukin-1 receptor antagonist (Primary)
- Indications Blepharoconjunctivitis
- Focus Therapeutic Use
- 04 Jan 2018 New trial record